Gout
📧 Sign up to get email alerts when something new happens for Gout.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-01-23Clinical Trial Update: Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects [Phase 2]
A Phase 2a study evaluating the combination of RDEA3170 and allopurinol in gout subjects has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-12-20Clinical Trial Update: RDEA3170 and Allopurinol Combination Study in Gout Subjects [Phase 1]
Phase 1 trial update evaluating RDEA3170 in combination with allopurinol for gout; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-10-13Clinical Trial Update: RDEA3170 Bioavailability Study [Phase 1]
The update notes completion and results posting of a Phase 1 bioavailability study of RDEA3170 for gout.
-
CLINICAL_TRIALS trial_result · 2017-10-11Clinical Trial Update: The Efficiency and Safety of Sodium Bicarbonate on Uric Acid in Patients With Asymptomatic Hyperuricemia or Gout [NA]
This document reports an update on a clinical trial evaluating the effectiveness and safety of sodium bicarbonate in reducing uric acid leve…
-
FDA approval · 2017-08-22FDA Approved: ALEVE GELCAPS — Supplemental Application (Bayer HealthCare LLC.)
FDA approved a supplemental application for ALEVE GELCAPS (naproxen sodium) by Bayer HealthCare LLC., expanding the product through a supple…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-08-15FDA Approved: ULORIC — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ULORIC (febuxostat) submitted by Takeda Pharmaceuticals America, Inc. The submission status …
-
FDA approval · 2017-08-10FDA Approved: KRYSTEXXA — Supplemental Application (Horizon Therapeutics USA, Inc.)
The FDA approved a supplemental application for KRYSTEXXA (pegloticase) from Horizon Therapeutics USA, Inc. This action grants an update to …
-
CLINICAL_TRIALS trial_result · 2017-07-27Clinical Trial Update: RDEA3170 and Febuxostat Combination Study in Gout Subjects [Phase 2]
Phase 2 study evaluating the combination of RDEA3170 and febuxostat in gout subjects has completed. Results have been posted (July 27, 2017)…
-
CLINICAL_TRIALS trial_result · 2017-07-18Clinical Trial Update: Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares [Phase 3]
A Phase 3 trial evaluating long-term rilonacept to prevent gout flares was terminated, with results posted in 2017.
-
FDA approval · 2017-06-22FDA Approved: INDOMETHACIN — Original Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark's Indomethacin generic under an Original Application; this entry records the approval status and product details.
-
CLINICAL_TRIALS trial_result · 2017-06-08Clinical Trial Update: Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective [Phase 3]
A Phase 3 study evaluating the safety and efficacy of canakinumab for patients with frequent gout flares who are contraindicated, intolerant…
-
CLINICAL_TRIALS withdrawal · 2017-05-11Clinical Trial Update: Allopurinol in Acute Gout [NA]
A clinical trial evaluating allopurinol for acute gout has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2017-05-02Clinical Trial Update: Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares [Phase 2]
Phase 2 study evaluating the safety and effectiveness of rilonacept for preventing gout flares completed; results were posted May 2, 2017.
-
CLINICAL_TRIALS trial_result · 2017-04-28Clinical Trial Update: Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE) [Phase 3]
This document reports a safety review from a Phase 3 trial (RE-SURGE) evaluating rilonacept to prevent gout exacerbations. Results for the t…
-
CLINICAL_TRIALS trial_result · 2017-04-28Clinical Trial Update: PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2) [Phase 3]
Phase 3 PRE-SURGE 2 trial completed evaluating a Regeneron investigational therapy to prevent gout flares triggered by urate-lowering drugs;…
-
CLINICAL_TRIALS trial_result · 2017-04-28Clinical Trial Update: Study Utilizing Rilonacept in Gout Exacerbations [Phase 3]
A Phase 3 trial evaluating rilonacept for acute gout flares has completed, with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-04-25Clinical Trial Update: Mild, Moderate and Severe Renal Impairment Study [Phase 1]
Phase 1 study evaluating pharmacokinetics in gout patients across mild, moderate, and severe renal impairment; the trial is completed and re…
-
CLINICAL_TRIALS withdrawal · 2017-04-20Clinical Trial Update: Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease [Phase 3]
A Phase 3 trial evaluating canakinumab for acute gouty arthritis in patients with chronic kidney disease has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2017-04-12Clinical Trial Update: Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout [Phase 2]
Phase 2 clinical trial evaluating the effect of topiroxostat on urinary albumin excretion in early-stage diabetic nephropathy with hyperuric…
-
CLINICAL_TRIALS trial_result · 2017-03-30Clinical Trial Update: Multiple Dose Study of SHR4640 in Healthy Subjects [Phase 1]
A Phase 1 multiple-dose study of SHR4640 in healthy subjects has completed, assessing safety and pharmacokinetics in the context of gout and…
-
FDA approval · 2017-03-10FDA Approved: NAPROXEN — Supplemental Application (Zameer Pharmaceuticals LLC)
FDA approved a supplemental application for Naproxen by Zameer Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2017-03-08Clinical Trial Update: Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients [Phase 2]
Phase 2 study of URC102 to assess efficacy and safety in gout and hyperuricemia has completed.
-
CLINICAL_TRIALS trial_result · 2017-02-28Clinical Trial Update: Single Dose Study of SHR4640 in Healthy Subjects [Phase 1]
This report notes the completion of a Phase 1 single-dose study of SHR4640 in healthy subjects to assess safety and pharmacokinetics for gou…
-
CLINICAL_TRIALS trial_result · 2017-02-14Clinical Trial Update: Study of FYU-981 in Hyperuricemia With or Without Gout [Phase 2]
Phase 2 trial of FYU-981 in hyperuricemia with or without gout has completed.
-
CLINICAL_TRIALS trial_result · 2017-01-30Clinical Trial Update: Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels [Phase 1]
Phase 1 study assessing safety and pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in individuals with elevated uric acid levels related…